Clinical trials: Corneal Graft Rejection
Corneal Endothelial Dystrophy, Corneal Edema
Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
The purpose of this study is to assess off-label use of loteprednol etabonate 0.25% ophthalmic suspension (Eysuvis) for prevention of immunologic rejection in the first year after Descemet membrane endothelial keratoplasty…
- Trial name
- NCT05136443
- Testing
- loteprednol etabonate 0.25% ophthalmic suspension
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Price Vision Group
Fuchs' Dystrophy, Bullous Keratopathy
Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)
The purpose of this study is to compare two different commonly used steroid dosing regimens after Descemet's membrane endothelial keratoplasty (DMEK) transplant surgery.
- Trial name
- NCT01448213
- Testing
- Prednisolone acetate, Fluorometholone
- Where
- 2 sites in United States, Germany
- Volunteers
- 264 people
- Sponsor
- Price Vision Group
Keratoconus, Fuchs' Endothelial Dystrophy
Immunosuppression During Penetrating Keratoplasty, Using a Subconjunctival Implant Releasing Dexamethasone : Tolerance and Safety Pilot Study
Immune rejection episodes after penetrating keratoplasty occur in 30% of patients and constitute one of the main factors reducing graft survival. They mainly occur during the first 18 months.
- Conditions
- Keratoconus, Fuchs' Endothelial Dystrophy, Congenital Hereditary Stromal Dystrophy of the Cornea
- Trial name
- IDEXACOR (NCT02834260)
- Testing
- Dexamethasone implant OZURDEX
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Penetrating Keratoplasty
Topical FK506 (Tacrolimus) for Prevention of Immune Reactions Following Penetrating Keratoplasty
Background: Patients following allogeneic keratoplasty are treated with topical and frequently with systemic steroids to prevent immune reactions. Steroids are known to yield good results, but exert a wide range of side effects.
- Trial name
- NCT00463723
- Testing
- FK506 0.06% (eye drops)
- Sponsor
- University Hospital Freiburg
Corneal Graft Rejection
Evaluation of the Efficacy of 2% Cyclosporine in Preventing Graft Rejection
Aim/ Objective: Study consists of 2 separate and distinct entities A. Evaluation of the efficacy of 2% cyclosporine in preventing graft rejection in primary grafts w/o high risk characteristics study 1 (PKP study) B.
- Trial name
- NCT02206789
- Testing
- Prednisolone acetate1%,, Prednisolone acetate1%, cyclosporine 2%
- Where
- India
- Volunteers
- 200 people
- Sponsor
- Aravind Eye Care System
Corneal Transplantation
Clinical Study on the Treatment of Mixed Component Cornea for High Risk Keratoplasty
Because of the immunologically privileged nature of the cornea, the graft rejection rate is less than 10% for low-risk keratoplasty.
- Trial name
- NCT04490902
- Testing
- Limbal transplantation combined with central penetrating keratoplasty
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Corneal Disease, Endothelial Corneal Dystrophy
Developing a Nationwide Registry to Track Longitudinal Clinical Outcomes of Corneal Surgery and Disease
The goal is to develop a nationwide registry to track longitudinal clinical outcomes of and store imaging data related to numerous corneal conditions.
- Conditions
- Corneal Disease, Endothelial Corneal Dystrophy, Corneal Transplant Failure, Corneal Transplant Rejection
- Trial name
- NCT06101017
- Testing
- Optical Coherence Tomography
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Nitin Vaswani
Corneal Transplantation, Graft Rejection
Collaborative Corneal Transplantation Studies (CCTS)
To determine whether histocompatibility matching of corneal transplant donors and recipients can reduce the incidence of graft rejection in high-risk patients.
- Trial name
- NCT00000137
- Testing
- Histocompatibility Matching
- Sponsor
- National Eye Institute (NEI)
Endothelial Graft Rejection
Efficacy of Topical Cyclosporine A for Treatment and Prevention of Graft Rejection in Corneal Grafts With Previous Rejection Episodes
The use of topical Cyclosporine A early after an episode of endothelial graft rejection after penetrating keratoplasty and continuing its administration for 6 months can reduce the course of that episode and recurrence of the…
- Trial name
- NCT01028443
- Testing
- Sandimmune, Artelose
- Where
- 2 sites in Iran
- Sponsor
- Shahid Beheshti University of Medical Sciences
Keratopathy
Immunosuppression After Repeat Keratoplasty
Purpose: To compare the efficacy of topical 0.03% tacrolimus with systemic mycophenolate mofetil (MMF) in preventing corneal allograft rejection after repeat keratoplasty.
- Trial name
- NCT04147390
- Testing
- prescribe topical 0.03 % tacrolimus, prescribe mycophenolate mofetil(MMF)
- Where
- Iran
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Corneal Transplant
Neovascularization Patterns in Corneal Graft Rejection
Corneal transplantation is the most commonly performed human tissue transplant worldwide. Over 40,000 corneal transplants occur in the US each year. .
- Trial name
- NCT01695655
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Michigan
Glycerin Cryopreserved Acellular Corneal Tissue, Deep Anterior Lamellar Keratoplasty
Deep Anterior Lamellar Keratoplasty (DALK) Using Acellular Corneal Tissue Promotes Corneal Allograft Survival in High Risk Patients
The purpose of this study is to study whether deep anterior lamellar keratoplasty (DALK) using acellular tissue will promote corneal graft survival in high risk patients.
- Conditions
- Glycerin Cryopreserved Acellular Corneal Tissue, Deep Anterior Lamellar Keratoplasty, High Risk Keratoplasty
- Trial name
- NCT01021046
- Testing
- DALK using GCCT, DALK using FCT
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Wenzhou Medical University
Corneal Graft Rejection, CD160
CD160 Expression in Corneal Vessels
Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to…
- Conditions
- Corneal Graft Rejection, CD160, Angiogenesis, Lymphangiogenesis
- Trial name
- NCT05009407
- Testing
- Immunohistochemistry and clinical analyses on patients and corneas
- Where
- France
- Volunteers
- 43 people
- Sponsor
- CHU de Reims
Corneal Diseases
Functional Antigen Matching in Corneal Transplantation
Penetrating keratoplasty is one of the most commonly performed transplantation surgeries. Graft rejection is a major complication.
- Trial name
- FANCY (NCT00810472)
- Testing
- HLA Matching, Penetrating keratoplasty
- Where
- Germany
- Volunteers
- 650 people
- Sponsor
- University Hospital Freiburg
Corneal Diseases, Cornea Transplant
Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk
This was a pivotal trial to determine whether LX201 reduces the likelihood of a graft rejection episode following corneal transplantation in patients at high immunological risk for rejection.
- Trial name
- NCT00447187
- Testing
- LX201
- Where
- 30 sites in United States, Germany
- Volunteers
- 368 people
- Sponsor
- Lux Biosciences, Inc.
Graft Rejection
Pathogenetic Risk Factors for Corneal Graft Rejection
There are many predictors that may influence the development of corneal graft rejection after penetrating keratoplasty. In our study investigators analysed the results of keratoplasty and the risk factors for graft rejection.
- Trial name
- NCT06281587
- Testing
- penetrating keratoplasty
- Where
- Russia
- Volunteers
- 93 people
- Sponsor
- The S.N. Fyodorov Eye Microsurgery State Institution
Corneal Transplant Rejection
Risk Factors for Human Corneal Graft Failure : a Monocentric Retrospective Observational Cohort
Keratoplasty is one of the most common grafts and penetrating keratoplasty is still the technique most used in the world, ahead of lamellar grafts, and is estimated to represent 70% of the total.
- Trial name
- NCT04791696
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Montpellier
Graft Rejection
Analysis of a Beneficial Effect of Prolonges Topical Steroid Treatment After Low-risk Penetrating Keratoplasty
PURPOSE: To assess the impact of duration of topical steroid treatment on the incidence of endothelial graft rejection following normal-risk penetrating keratoplasty (PK).
- Trial name
- NCT00450996
- Testing
- Topical Steroids
- Volunteers
- 400 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Corneal Transplantation, Corneal Graft Rejection
Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty
This study will evaluate the use of LX201 to prevent future graft rejection episodes and/or graft failure in patients who have undergone corneal transplantation and who have recently experienced a rejection episode due to an…
- Trial name
- NCT00447642
- Testing
- LX201
- Where
- 30 sites in United States, Germany
- Volunteers
- 122 people
- Sponsor
- Lux Biosciences, Inc.